astegolimab (RG 6149) - Amgen, Roche
Astegolimab: NME submission in US for COPD in 2025 (Roche) - Oct 23, 2025 - Q3 2025 Results: Regulatory submission in EU for COPD in 2025 
EMA filing • FDA filing Chronic Obstructive Pulmonary Disease • Immunology
https://assets.roche.com/f/176343/x/a22e1c7d2f/irp251023.pdf
 
Oct 23, 2025
 
 
22017498-2f54-4156-a49f-e9f3ed160de0.png